This metaanalysis was performed to determine the optimal use of antiegfr mab in the treatment of metastasized colorectal cancer mcrc. This openlabel trial of the treatment of colorectal cancer with cetuximab, a chimeric monoclonal antibody against the epidermal growth factor receptor egfr, showed that among patients with color. Epidermal growth factor receptor egfr, also known as erbb1 or her1 inhibitors are medicines that bind to certain parts of the egfr and slow down or stop cell growth. Extended ras mutations and antiegfr monoclonal antibody survival benefit in metastatic colorectal cancer. The stromal and immune landscape of colorectal cancer. The median duration of survival in patients with metastatic colorectal cancer mcrc is now around 30 months, largely owing to the use of sequential lines of chemotherapy combined with. Colorectal cancer is a common malignancy and the second leading cause of cancerrelated death in the united states. One of the most promising targets is the epidermal growth factor receptor egfr, a member of the subclass i of the receptor tyrosine kinase superfamily which is overexpressed in.
Colorectal cancer predictive testing for antiegfr therapy indications for ordering indicated for individuals with metastatic colorectal cancer crc to guide treatment with antiegfr monoclonal. Antiepidermal growth factor receptor egfr antibodies antiegfrab are effective in a subgroup of patients pts with metastatic colorectal cancer crc. Cancer of the colon or rectum that has spread to other organs metastatic colorectal cancer is a commonly occurring disease that usually cannot be surgically removed. Egfr, performed using an egfr pharmdx kit mouse antihuman egfr mab clone 218c9, in clinical specimens before and after antiegfr mab therapy in colorectal cancer patients showed a. In kras wildtype wt patients treated with cetuximabcontaining regimens in first line. Colon cancer and the epidermal growth factor receptor. Targeting the epidermal growth factor receptor egfr either alone or in combination with chemotherapy is e ective for patients with ras wild type metastatic colorectal cancer mcrc.
Colon cancers seen in egfr mutant specimens demonstrated an. Genomic characterization of intrinsic and acquired resistance to. In vitro, a correlation between ecadherin expression and growth inhibition by egfr inhibitors was observed in colorectal cancer cells. Activation of signal pathways and the resistance to anti. Mechanisms of resistance to antiegfr therapy in colorectal cancer article pdf available in oncotarget 83 july 2015 with 468 reads how we measure reads. However, there are a few studies show the efficacy and. From heterogeneity to convergent evolution sandra misale 1,2, federica di nicolantonio 1,2, andrea sartorebianchi 3, salvatore siena 3, and. Targeting the epidermal growth factor receptor egfr either alone or in combination with chemotherapy is effective for patients with ras wild. Epidermal growth factor receptor egfr inhibitors are valuable therapeutics in metastatic colorectal cancer mcrc. Antiepidermal growth factor receptor egfr treatment in. Pdf antiegfr treatment in patients with colorectal cancer. Her2 amplification and antiegfr sensitivity in advanced. Epidermal growth factor receptor pathway mutations and.
As of july 1st 2010, only records submitted with full text will be accepted in the academic bibliography. Colorectal cancer predictive testing for antiegfr therapy. Antiegfr agents and colorectal cancer patients with kras. Precision medicine in metastatic colorectal cancer. If the inline pdf is not rendering correctly, you can download the pdf. Adjuvant fluoropyrimidinebased chemotherapy for 6 months is standard of care in patients. The cmyc expression was evaluated in 121 ras and braf wildtype mcrc. The rationale for antiegfr therapies in cancer treatment relies on the role that egfr may play in tumorigenesis and the frequent overexpression or hyperactivation of egfr noted in. Pdf mechanisms of resistance to antiegfr therapy in. Clinical relevance of egfr and krasstatus in colorectal cancer. Molecular alterations in kras are associated with acquired resistance to antiepidermal growth factor receptor egfr treatment in colorectal cancer. The aim of this study was to investigate the differences.
Pdf on feb 17, 2012, camilla qvortrup and others published antiegfr treatment in patients with colorectal cancer find, read and cite all the research you need on researchgate. Antiegfr therapy showed promising efficacy for certain patients with nonv600 brafmutated metastatic colorectal cancer, according to results of a multicenter, pooled analysis published. Several other alterations, such as presence of met. Egfr downregulation after antiegfr therapy predicts the. Resistance to antiegfr therapy in colorectal cancer. Egfr antibodies in resectable metastatic colorectal liver. This genomic and transcriptomic analysis of the cetuximab resistance.
Antiegfr antibody is approved for the treatment of patients with kras wildtype metastatic colorectal cancer. Cancer blockade of egfr and mek intercepts heterogeneous mechanisms of acquired resistance to antiegfr therapies in colorectal cancer sandra misale,1,2 sabrina arena,1,2 simona lamba,1,2. Antiegfr mab is reported to induce egfr internalization in colorectal cancer cells. Antiegfr monoclonal antibodies moabs, such as cetuximab or panitumumab, in. Mechanisms of resistance to antiegfr therapy in colorectal cancer. What are egfr inhibitors in stage iv colon cancer patients. Currently, the best predictor of efficacy is the absence of mutations in kras and nras genes. Whether we can justify profiling all colorectal cancer patients from an insurance point of view is. Pdf should antiegfr agents be used in rightsided ras wild. Genomic and transcriptomic determinants of therapy. The major challenge is the identification of patients who would benefit from treatment.
In the united states, cancer is the most common cause of death among people under the age of 85 years, and colorectal cancer is the second most common cause of death from cancer. Antiegfr therapy effective for certain patients with braf. Antiegfr therapy in rightsided metastatic colorectal. However, the biological relevance of egfr internalization with antiegfr mab is unknown. Colorectal cancer crc is one of the most commonly diagnosed cancers in both genders second in females and third in males 1. A molecularly annotated platform of patient derived.
As researchers have learned more about the gene and protein changes in cells that cause colorectal cancer, they have developed newer drugs to specifically target these changes. The discovery that ras mutations could be used to predict sensitivity and resistance to antiepidermal growth factor receptor egfr therapy in patients with colorectal cancer crc has. Panitumumab alone for maintenance treatment in advanced. The response to treatment with antiegfr antibodies is thus limited to patients without a mutation in the kras oncogene. Implementing antiepidermal growth factor receptor egfr. Epidermal growth factor receptor egfr inhibitors for. In ontario, patients with advanced colorectal cancer who are refractory to chemotherapy may be offered the targeted antiegfr treatments cetuximab or panitumumab. Emergence of kras mutations and acquired resistance to anti egfr therapy in colorectal cancer. Mutations in kras, nras, and braf and amplification of erbb2 and met drive. Several studies have demonstrated the antitumor effects of ginseng. Antiepidermal growth factor receptor antiegfr monoclonal antibody has established its role in the systemic therapy of. Alterations in the transcriptional factor cmyc could be involved in the antiegfr resistance in metastatic colorectal cancer mcrc. Optimizing antiegfr therapy in colorectal cancer ramon salazar1 and fortunato ciardiello2 treatment with antiegfr monoclonal antibodies has been successfully integrated in the continuum of care for. Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from therapy with anti epidermal growth factor receptor egfr antibodies, which calls for the identification of novel biomarkers for better personalized medicine.
Eligibility for these treatments is based on the kras status of their tumour, derived from tissue collected from surgical or biopsy specimens. Kras testing in the selection of colorectal patients for. We also summarize the clinical evidence regarding antiegfr monoclonal. Antiegfr antibodies are effective in therapies for latestage colorectal cancer crc. Targeting epidermal growth factor receptor egfr in. Antiegfr agents detrimental in colorectal cancer patients with kras mutation. Emergence of kras mutations and acquired resistance to. Kras testing for antiegfr therapy in advanced colorectal. Molecular analysis of colorectal cancer is now mandated before initiation of antiegfr therapy and directly impacts treatment options and outcomes.
The timeline charts the key the timeline charts the key steps of the anti egfr targeted therapies approval for mcrc treatment together with the most signi. Cetuximab for the treatment of colorectal cancer nejm. The egfrtargeted antibodies cetuximab and panitumumab are used to treat metastatic colorectal cancers. Mechanisms of innate and acquired resistance to antiegfr therapy. Pdf monoclonal antiegfr antibodies in the treatment of. Treatment with antiegfr monoclonal antibodies has been successfully integrated in the continuum of care for metastatic colorectal cancer. Despite biomarker stratification, the antiegfr antibody cetuximab is only effective against a subgroup of colorectal cancers crcs. Egfr treatment as it increases the risk factors for colorectal cancer. Furthermore, obesity may decrease the effectiveness of anti. Development of the anti egfr antibodies cetuximab and panitumumab in metastatic colorectal cancer mcrc. Targeted therapy drugs work differently from standard chemotherapy chemo drugs. We are particularly indebted to simona lamba for generating. Colorectal cancer crc is the third most frequent neoplastic disorder and is a main cause of tumorrelated mortality, as many patients progress to stage iv metastatic crc.
1363 742 860 751 868 394 1397 1546 1118 1338 1008 383 1128 1344 1487 1171 387 186 38 152 352 307 727 236 1069 1553 63 1144 1163 246 586 304 1449 1547 960 862 1048 49 540 1431 839 652 1099 1060 1169